The ideal therapy for single gene disorders would be repair approach, we have overexpressed the gene encoding of the mutated disease genes. Homologous recombination hRAD51, a protein with homologous DNA pairing and is one of several cellular mechanisms for the repair of DNA strand exchange activities, in human cells and measured damage. Recombination between exogenous DNA and its effect on gene targeting. We report a two-to three-fold homologous chromosomal loci (gene targeting) can be increase in gene targeting, and enhanced resistance to used to repair an endogenous gene, but the low efficiency ionising radiation in hRAD51-overexpressing cells with no of this process is a serious barrier to its therapeutic potenobvious detrimental effects. These observations provide tial. Recent progress in the isolation and characterisation valuable genetic evidence for the involvement of hRAD51 of mammalian genes and proteins involved in DNA recomin both gene targeting and DNA repair in human cells. Our bination has raised the possibility that the cellular biochemdata also establish overexpression of recombination genes istry of recombination can be manipulated to improve the as a viable approach to improving gene targeting efficiency of gene targeting. As an initial test of this efficiencies.
Introduction
Many inherited genetic disorders, such as cystic fibrosis and haemophilia, are caused by defined mutations in single disease genes. Gene therapy strategies that are considered for such diseases usually involve the introduction of an additional, mutation-free copy of the disease gene into the cells of an appropriate tissue. Problems with such gene augmentation strategies include inappropriate or unstable expression of the new gene, safety concerns arising from random integration into the host genome and limitations on the size of gene that can be introduced. Repair of the mutated endogenous gene would avoid all of these problems and this can be achieved experimentally by gene targeting:homologous recombination between transfected DNA and homologous sequences in the genome. 1 The efficiency of gene targeting, however, is generally low and this has prevented it from being widely considered as an approach to gene therapy.
The inefficiency of gene targeting stems from the low frequency with which DNA integrates at its target locus and the relatively high frequency with which it integrates at random loci. [1] [2] [3] [4] Selection and screening procedures that allow unwanted random integrants to be eliminated have been developed, 5, 6 but the more fundamental problem of the low absolute targeting frequencies has been more difficult to tackle. Some improvements to absolute targeting frequencies can be made by linearising the targeting con-
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Received 8 December 1998; accepted 26 February 1999 struct and maximising the length and quality of its homology with the target locus. [7] [8] [9] [10] Substantial increases have been obtained by engineering double-strand breaks (DSBs) in the target locus, but this approach is not currently applicable to single-step targeting strategies. [11] [12] [13] [14] Recent approaches to the problem have included the use of short fragments of DNA, 15 DNA/RNA oligonucleotides (reviewed in Ref. 16 ), modified selection conditions 17 and adeno-associated virus vectors 18 and these have generated some dramatically improved targeting efficiencies. The reasons for the relatively high targeting efficiencies in these studies are unclear and it remains to be seen if these approaches can be generally applied. Additional approaches to improving gene targeting efficiencies based on a knowledge of the mammalian recombination machinery are therefore highly desirable.
Genetic and biochemical studies have shown that homologous recombination in yeast is mediated by the RAD52 epistasis group of genes. 19 Vertebrate homologues of these genes have been recently identified. [20] [21] [22] The high degree of sequence conservation from yeast to man and the similarity of in vitro biochemical function suggested that the vertebrate homologues were also involved in homologous recombination. RAD51, a eukaryotic homologue of E. coli recA, seems to play a central role in the process with its DNA pairing and strand exchange activities. 23, 24 A direct demonstration for involvement of the vertebrate RAD52 group genes in various types of homologous recombination requires experiments in which expression of a particular gene is either suppressed or elevated in living cells. Thus gene targeting was shown to be impaired in both mouse ES cells and in chicken B cells if RAD54 gene expression was eliminated 25, 26 and to a lesser extent, if RAD52 was inactivated. 27, 28 Equivalent experiments with RAD51 have not been possible because of the lethal effects of inactivation. 29 Resistance to DNA damage, presumably reflecting DNA repair by homologous recombination, is also severely reduced upon RAD54 or RAD51 inactivation. 25, 26, 30 Overexpression of S. cerevisiae RAD52 in human cells, 31 of human RAD52 in monkey cells 32 and of hamster RAD51 in CHO cells 33 has been shown to promote ionising radiation resistance and intrachromosomal or extrachromosomal homologous recombination. However, in none of these overexpression studies was the effect on gene targeting itself measured. This is important because the different forms of homologous recombination can involve subtly different mechanisms. [34] [35] [36] Given the apparently key role of RAD51 in homologous recombination, we reasoned that increased levels of the protein may favour gene targeting. We have therefore overexpressed the human gene encoding RAD51 (hRAD51) constitutively in human cells, and have found elevated gene targeting frequencies at two different loci. Additionally, increased expression of hRAD51 rendered the cells more resistant to high doses of ionising radiation. These findings strongly support the involvement of hRAD51 in homologous recombination in vivo, and suggest that the amount or basal activity of the protein can be rate limiting for the process. They also show that overexpression of homologous recombination proteins is a viable approach for increasing gene targeting in human cells.
Results

Overexpression of hRAD51
Polyclonal pools (approximately 500 clones per pool) of HT1080 cells overexpressing hRAD51 were obtained by transfection with phRAD51neo or phRAD51Rneo as described under Materials and methods. These plasmids differ only in the relative orientation of the hRAD51 and neomycin phosphotransferase (neo) expression cassettes, and allow constitutive hRAD51 expression from a cytomegalovirus (CMV) promotor. Similar numbers of G418-resistant colonies (4-5.5 × 10 −4 colonies per transfected cell) were obtained by transfection of the control plasmid pBSneo, phRAD51neo and phRAD51Rneo.
The level of hRAD51 overexpression in stably transfected cells was analysed by Western blot, using a polyclonal antibody against hRAD51 (Figure 1a ). hRAD51 is detected in untransfected HT1080 cells as an approximately 40 kDa protein. Independent, polyclonal pools of transfected cells showed reproducible levels of hRAD51 protein: cells containing the control plasmid had hRAD51 levels similar to those in wild-type HT1080 cells, while a four-fold overproduction of the protein was observed in cells transfected with either phRAD51neo or phRAD51Rneo ( Figure 1a and data not shown). Analysis of the level of hRAD51 protein in clonal populations of either phRAD51neo-or phRAD51Rneo-transfected HT1080 cells showed wide variations, including a minority of clones that did not overexpress the transgene (data not shown). Thus, the four-fold overproduction of hRAD51 in polyclonal pools of cells transfected with the hRAD51 transgene should be considered an average value.
We further characterised hRAD51 overexpressing cells by analysing growth rates and cell ploidy. No difference in growth rate was found in polyclonal pools of HT1080 cells transfected with phRAD51neo or phRAD51Rneo when compared with pBSneo-transfected or wild-type cells (data not shown). This, together with the similar stable transfection frequencies observed with all three plasmids, suggests that hRAD51 overexpression does not affect viability or growth rate in HT1080 cells.
To study cell ploidy and gross cell-cycle distribution in our polyclonal cell pools we performed FACS analyses of propidium iodide-stained cell nuclei. HT1080 cell populations normally include a minor fraction of tetraploid cells, and display a major G1 peak and a smaller G2/M peak (Figure 1b) . hRAD51 overexpressing cells are also mostly diploid. However, we observed a small reduction in the number of diploid cells, and a concomitant increase in tetraploid cells, in hRAD51 overexpressing cells compared with pBSneo-transfected controls ( Figure 1b and Table 1 ). We have noted similar ploidy variations between wild-type HT1080 cultures, so those differences may not be related to hRAD51 overexpression.
Hypoxanthine phosphoribosyl transferase (HPRT) gene targeting system
We set up an HPRT-based system to quantify gene targeting in human cells (Figure 2a) . HPRT is an X-linked, single-copy gene in diploid human male cells, and its inactivation leads to 6-thioguanine (6-TG) resistance. We cloned an 8.5-kb DNA fragment containing HPRT exons II and III from a genomic library of HT1080 DNA. A replacement-type gene targeting construct (pHPRThyg) was produced from this clone by insertion of a hygromycin B phosphotransferase (hyg) expression cassette within HPRT exon II. Upon transfection of pHPRThyg into HT1080 cells, gene targeting was quantified as the number of colonies resistant to both hygromycin and 6-TG. This double selection ablates spontaneous HPRT − mutants. Random integration of the transgene was estimated from the number of hygromycin-resistant colonies (which include a small fraction of targeted clones). Southern blot analyses confirmed the expected genomic structure of the HPRT locus in selected colonies resistant to either hygromycin or both 6-TG and hygromycin ( Figure  2b ). Using this system, standard gene targeting frequencies were approximately 5 × 10 −6 targeted clones per transfected cell, while the ratio gene targeting:nonhomologous recombination was approximately 1:110.
hRAD51 overexpression increases gene targeting of HPRT To test whether hRAD51 overexpression promotes gene targeting we quantified this process in the polyclonal pools of HT1080 cells overproducing the protein. In each of two separate experiments, four independent pools of control cells or hRAD51 overexpressing cells were transfected with pHPRThyg to estimate the frequencies of gene targeting at the HPRT locus and of random integration. We observed an average 2.1-fold increase in the absolute frequency of gene targeting of HPRT upon hRAD51 overexpression (Table 2 ). In contrast, random integration frequencies were not significantly altered. This is reflected in an average 2.2-fold increase in the ratio gene targeting: nonhomologous recombination, from approximately Table 2 ) reveals some of the day-to-day variation in the absolute frequencies of gene targeting and random integration that we have observed. However, the increases in gene targeting and in the ratio gene targeting:nonhomologous recombination are statistically significant within experiments (t test, Table 2 ) and even more significant when a joint analysis of variance (ANOVA) of experiments 1 and 2 is performed. Thus, we obtained P values of Ͻ0.0001 in the ANOVA for the increases in gene targeting and the ratio gene targeting:nonhomologous recombination in hRAD51 overexpressing cells. Again, no significant change was detected in random integration frequencies (P Ͻ 0.63). We conclude that overexpression of hRAD51 in HT1080 cells increases the frequency of gene targeting at the HPRT locus, while the random integration frequency is not altered.
Figure 1 Characterisation of hRAD51 overexpressing cells. (a) Overexpression of hRAD51. Wild-type HT1080 cells (wt) or cells stably transfected with the indicated plasmids were analysed by Western blot with serum against hRAD51. The blots were re-probed with anti-actin antibody to control for loading differences. (b) Ploidy analysis in cells overexpressing hRAD51. Wild-type cells or pooled stable transfectants of the indicated plasmids were stained with propidium iodide and analysed for DNA content by FACS.
hRAD51 overexpression increases gene targeting of 6-16
To analyse the effect of hRAD51 overexpression on gene targeting at a non-selectable locus we chose the interferon inducible 6-16 gene. We targeted this gene using a previously described promotor-trap strategy, 37 but our targeting vector p6gpt was reconstructed with HT1080-isogenic DNA. This strategy is described in Figure 3a . Briefly, the 6-16 gene is transcribed in response to interferon (IFN) treatment. Upon gene targeting, the promotorless xanthine-guanine phosphoribosyl transferase (gpt) gene from the targeting construct becomes IFN-inducible, endowing the cells with IFN-dependent mycophenolic acid (MPA) resistance. IFN-independent MPA resistance can arise from random integration events if the promotorless gpt gene comes under the control of heterologous promotors. We screened MPA-resistant colonies for gene targeting by duplex PCR with two pairs of oligonucleotides. The oligonucleotide pair O1/O2 was designed to 37 The oligonucleotide pair oHPRT-3/oHPRT-4 was used as a control for the presence of template DNA, and generates a 0.7-kb DNA fragment (Figure 3b ). Clones were scored as targeted at the 6-16 locus if both the 1-and 0.7-kb bands were detected, and counted as random gpt activation events if only the HPRT-derived, 0.7-kb band was observed. This strategy allowed us to estimate the ratio of 6-16 gene targeting to random activation of gpt, but not the absolute frequencies of both processes. However, we have described in the previous section that the frequency of random integration is not affected by hRAD51 overexpression. Thus, we have considered the frequency of random activation of gpt as a constant, and variations in the ratio of 6-16 gene targeting:random gpt activation are interpreted as changes in the frequency of gene targeting.
After transfection of control and hRAD51 overexpressing cells with p6gpt, selection was carried out in the presence of IFN. Screening of MPA-resistant colonies by duplex PCR showed that in control cells, the ratio gene targeting:random activation of gpt was 1:2.5 (Table 3) . However, in cells overexpressing hRAD51 we detected an average 3.2-fold increase in that ratio, whereby gene targeting events outnumbered random activation of gpt 1:0.8. This increase is statistically significant in an ANOVA, with P Ͻ 0.02. We conclude that the efficiency of gene targeting at the 6-16 locus is elevated in HT1080 cells overexpressing hRAD51.
hRAD51 overexpression enhances DNA damage resistance We tested the radiation resistance of HT1080 cells overexpressing hRAD51 in a plating efficiency assay. Two control samples and two hRAD51 overexpressing cell samples (one each transfected with phRAD51neo or phRAD51Rneo) were gamma-irradiated with doses between 2.5 and 15 Gy, and plated out in triplicate. We observed enhanced survival in hRAD51 overexpressing cells, reaching a maximum six-fold increase at 12.5 and 15 Gy (Figure 4 ). Statistical analysis shows that the difference between control and hRAD51 overexpressing cells increases significantly with the irradiation doses (ANOVA P Ͻ 0.006).
Discussion
Gene targeting would be a powerful tool in gene therapy if its efficiency could be reliably and significantly increased. 1 Increases in efficiency would also facilitate the application of gene targeting to the analysis of gene function in mice 38 and somatic cells. 39 In this study, we aimed to test whether elevated levels of hRAD51, a key player for in vitro homologous recombination, could increase the frequency of gene targeting in human cells. We constitutively expressed hRAD51 in human cells and detected by Western analyses a four-fold increase of hRAD51 protein 
Figure 4 Survival of hRAD51 overexpressing cells to ionising radiation. Plating efficiency experiments after gamma-irradiation were carried out with pools of HT1080 cells stably transfected with pBSneo (open circles) or the hRAD51 overexpressing plasmids (black circles). Points represent averages of two independent control or hRAD51-transfected pools in a representative experiment. 100% Survival corresponds to the plating efficiency of unirradiated samples.
in pooled transfected cells. Gene targeting experiments involving two independent target loci, HPRT and 6-16, showed a two-to three-fold stimulation of the process in pools of hRAD51 overexpressing cells compared with control pools. This strongly suggests that hRAD51 is involved in the gene targeting reaction in living cells and that the amount or basal activity of the protein may be rate-limiting. Although more profound increases in efficiency will be required for therapeutic gene targeting, our data establish the important principle that the recombination machinery can be manipulated to promote gene targeting in human cells. Given the established involvement of RAD52 and RAD54 in gene targeting in vertebrate cells, [25] [26] [27] [28] further manipulations of RAD gene expression with the aim of increasing the frequency of gene targeting are now an attractive proposition.
A potential drawback of increasing gene targeting by enhancing homologous recombination activity is a possible concomitant increase in genome instability. Elevated homologous recombination is a characteristic of immortal cells, and it has been hypothesised that it could contribute to the genomic instability characteristic of cell transformation to immortality and of cancer cells. 40, 41 Our DNA content analyses of hRAD51 overexpressing cells reveal profiles similar to those of control cells, the only difference being a small increase in the fraction of tetraploid cells in hRAD51 transfectants. This suggests that no major changes in cell ploidy or cell-cycle distribution have taken place in the limited period of tissue culture (up to five passages) used for the experiments included in this report. Longer periods of culture show stable DNA content profiles in most cases, even though occasional shifts to tetraploidy in clonal and pooled stable hRAD51 transfectants were observed, and the growth rate of pooled hRAD51 transfectants was not significantly different to that of control cells (our unpublished results). Additionally, it has been shown that RAD52 overexpression has no obvious effect on the frequency of sister chromatid exchange. 31 In any case, the window of opportunity for any unwanted rearrangements could be reduced by using systems for the inducible or transient expression of RAD genes.
It has been recently reported that three-fold overexpression of hamster RAD51 in hamster cells increases 20-fold the frequency of intrachromosomal homologous recombination. 33 We have shown that gene targeting increases two-to three-fold upon a similar level of hRAD51 overexpression in human cells. There are several reasons that may account for the difference in the stimulation factors. The recombination substrate used in hamster cells was a chromosomal plasmid, which might have a chromatin structure and/or modifications more prone to recombination than the unmodified chromosomal loci of the targeting reaction. There may be cell type-specific differences in recombination activities between CHO and HT1080 cells or mechanistic differences between intrachromosomal recombination and gene targeting. In this respect, it is interesting to note that the mammalian RAD51 gene family contains at least seven different genes whose specific functions are under investigation. 20, [42] [43] [44] [45] [46] It is possible that different homologous recombination processes make use of variable sets of gene products, or that accessory proteins are present at variable levels. hRAD51 overexpression might only enhance gene targeting threefold before another component of the recombination machinery becomes limiting, and this could be different for intrachromosomal recombination.
In the present study, we also quantified random integration of the HPRT targeting construct in HT1080 cells, and found no significant difference between hRAD51 overexpressing cells and control cells ( Table 2 ). The increase in gene targeting upon hRAD51 overexpression in the absence of any effect on random integration may point to the independence of homologous and nonhomologous recombination pathways. A similar conclusion was drawn from studies in which random integration was significantly inhibited with only marginal effects on homologous recombination. 47, 48 Given the involvement of RAD genes in the repair of DSBs by homologous recombination, we were interested to test whether hRAD51 overexpression also led to an enhancement of ionising radiation resistance in human cells. We tested radiation doses between 2.5 and 15 Gy, and found increased survival in hRAD51 overexpressing cells compared with control cells, confirming the involvement of hRAD51 in the repair process. The increase in radiation survival of hRAD51 overexpressing cells seemed to be dose-dependent, with a maximum approximately six-fold enhancement at 12.5 and 15 Gy. It is unclear to us why the enhancement is dose-dependent. However, we have observed that the time required for a colony to grow to a given size increases with the irradiation doses (unpublished results). This may point to an extended cell cycle arrest at higher doses, which may favour increased DNA repair in the presence of overproduced hRAD51. Similar findings have been recently reported in RAD51 overexpressing CHO cells, where it was observed that radiation resistance is particularly increased in cells synchronised in late S/G2 phases. 33 Thus, the data from RAD51 overexpression in human and hamster cells are consistent with a role of the protein in the repair by homologous recombination of irradiation-induced DSBs. Additionally, RAD51 is likely involved in the repair of endogenous DNA damage: RAD51 repression in chicken DT40 cells leads to isochromatid breaks, accumulation of cells in the G2/M checkpoint and cell death, suggesting that RAD51 plays an essential role in the repair of lesions generated during DNA replication in vertebrate cells. 29 Taken together, all these data suggest that RAD51 is a key player for in vivo repair by homologous recombination of endogenous or exogenously induced DSBs.
In conclusion, our data show that hRAD51 is involved in the repair of radiation-induced DNA damage and in gene targeting, and indicate that overexpression of RAD genes is a viable strategy for increasing the absolute frequency of gene targeting. Such approaches may facilitate the production of targeted gene mutations in somatic cells and in mice and, if greater improvements are achieved, gene therapy by gene targeting-mediated correction may become a practical prospect.
Materials and methods
DNA cloning and analysis
We used standard procedures for DNA manipulation. 49 The control plasmid pBSneo was obtained by cloning a blunt-ended AccI/BamHI fragment from pSV2neo, 50 containing the neo gene, into SmaI-digested pBSIIKS+ (Stratagene, Amsterdam, The Netherlands). We obtained pCMV51 from Dr Dennis Hellgren, Karolinska Institute, Huddinge, Sweden. This plasmid is derived from pCMV4 51 by insertion of a fully sequenced, PCR-amplified hRAD51 cDNA (nucleotides 222-1284 in GenBank entry D14134) into the KpnI site. The hRAD51 expression plasmids phRAD51neo and phRAD51Rneo were produced by cloning an end-filled SexAI/PvuII hRAD51 expression cassette from pCMV51 into the EcoRV site of pBSneo. hRAD51 is expressed constitutively using the CMV immediate-early promotor and human growth hormone terminator in phRAD51neo and phRAD51Rneo, plasmids that differ only in the transcriptional orientation of the human transgene.
HPRT DNA was obtained screening a library of genomic DNA from HT1080 cells in DASH II (kindly given by Dr Elizabeth Fisher, Imperial College School of Medicine, London, UK) by a PCR method. 52 An 8.5-kb HPRT fragment starting at the SwaI site in intron I, 53 including HPRT exons II and III, and with a DASH-derived NotI 3Ј end, was subcloned into SmaI/NotI-digested pBSIIKS+ to produce pBSHPRT. The targeting construct pHPRThyg is a derivative of pBSHPRT, created by insertion of an end-filled BamHI fragment containing the hyg expression cassette from pSV2hygro into the SexAI site of HPRT exon II. Southern screening for HPRT gene targeting was done using a 314-bp BsaBI/XcmI probe (nucleotides 6995-7320 in the HPRT genomic sequence, GenBank entry M26434) and genomic DNA from amplified HT1080 colonies.
Plasmid p6gpt was used to target the human 6-16 gene. It contains a pBSIIKS+ backbone, 6.2-kb of 6-16 genomic sequence including all five exons of the gene but lacking the promotor, and a promotorless gpt marker inserted at the Asp718 site of intron I. P6gpt is HT1080-isogenic, and was built following the procedure previously described for pRC1. 37 Screening for 6-16 gene targeting was done by duplex PCR reaction on isolated MPA-resistant colonies. Template preparation, PCR reaction conditions and oligonucleotides O1/O2 used to screen for 6-16 gene targeting have been previously described. 37 However, we included an extra pair of primers (oHPRT-3: 5Ј-TTCA-CAAGTCTCCAGCCATG and oHPRT-4: 5Ј-ACAT-ACCTTGCGACCTTGAC, corresponding to nucleotides 34532-34551 and 35025-35006, respectively, in the HPRT genomic sequence) for amplification of HPRT exon VI as a control for the presence of template DNA. Because the HPRT-derived PCR product was always more intense than the 6-16-derived product in the duplex reaction, we scored only reactions in which the HPRT PCR signal was sufficiently intense to be sure that a possible 6-16-derived band would be detectable.
Cell culture, transfection and irradiation
The human fibrosarcoma HT1080 cell line 54 was grown in DMEM (Gibco-BRL, Paisley, UK) supplemented with 10% heat-inactivated calf serum. For transfection, HT1080 cells were grown to pre-confluence, trypsinised and electroporated as previously described, 37 with the following changes. After trypsinisation and washing, cells were resuspended at 10 7 cell/ml (for stable transfection of hRAD51) or 2 × 10 7 cell/ml (for gene targeting experiments), and 800 l of cell suspension were mixed with 8 g of plasmid construct and electroporated. Drug selection was started 48 h after transfection, and was maintained throughout cell culture.
HT1080 cells overexpressing hRAD51 were produced by transfection of Asp700-digested phRAD51neo or phRAD51Rneo. Control cells were transfected with Asp700-digested pBSneo. Asp700 linearises all these plasmids by cutting at a unique site within the vector back-bone. After electroporation cells were selected in 400 g/ml G418. Polyclonal pools of G418-resistant cells were obtained by trypsinisation of plates containing approximately 500 colonies. Several independent pools of cells transfected with each plasmid were obtained, amplified and frozen. These polyclonal transfectants were subsequently cultured in 200 g/ml G418, up to a maximum of five passages.
To quantify HPRT gene targeting, four independent control cell pools and four hRAD51 overexpressing cell pools (two each from phRAD51neo and phRAD51Rneo transfections) were used in each experiment. Cells were transfected with SalI-digested pHPRThyg. Cells from each sample (15 × 10 6 ) were plated out at 2.5 × 10 6 cells/175 cm 2 plate, treated with hygromycin (100 g/ml) from day 2 to day 5 after electroporation, and with hygromycin (100 g/ml) plus 6-TG (15 g/ml) from day 5 to day 12. Delaying the addition of 6-TG for 3 days maximised the yield of doubly resistant colonies. Random integration of the targeting construct was quantified in triplicate dishes containing 10 5 transfected cells each, selected with hygromycin from day 2 to day 9 after electroporation. Colonies were stained with crystal violet at the end of the selection procedure. 6-16 Gene targeting experiments were carried out with two control cell pools and two hRAD51 overexpressing cell pools (one each from phRAD51neo and phRAD51Rneo transfections) by electroporating SalI-digested p6gpt. Transfected cells (3 × 10 7 ) from each sample were plated out at 2.5 × 10 6 cells/175 cm 2 plate and selected with 10 g/ml MPA in the presence of 100 IU/ml Wellferon (a mixture of human type I IFNs, Glaxo-Wellcome) and 100 g/ml xanthine for 15-16 days. MPA-resistant colonies were screened for 6-16 gene targeting by PCR.
For radiation resistance measurements, cells were trypsinised and resuspended at 5.5 × 10 6 cells/ml in DMEM. Gamma irradiation of 500 l-cell suspensions was carried out in a CIS BIO IBL367 137 Cs irradiator, at a dose rate of 1.85 Gy/min. Cells were washed with DMEM after irradiation and plated out in triplicate. The percentage of survival was calculated from the number of colonyforming units relative to a mock-treated cell sample.
Western blotting
Immunoblots for detection of hRAD51 were done with HT1080 cell extracts. Cells were trypsinised, washed and lysed with sample buffer. 55 Extracts were heated in boiling water for 5 min, and insoluble debris removed by spinning at 10 000 g for 10 min. Samples (5 g of protein) were loaded on to 12% SDS-PAGE gels and transferred to Immobilon-P membranes (Millipore). hRAD51 was detected with rabbit polyclonal antiserum FBE-2 (kindly given by Dr Fiona Benson, Imperial Cancer Research Fund, South Mimms, UK), using a 1:1000 dilution. A secondary goat anti-rabbit immunoglobulin antiserum conjugated to horseradish peroxidase (P0448, DAKO) was used at a 1:2000 dilution. Detection was done with an ECL system (Amersham Life Sciences) using pre-flashed Hyperfilm ECL (Amersham Life Sciences). To control for gel loading membranes were re-probed with rabbit antiactin antibody (A2066, Sigma), using a 1:250 dilution, followed by incubation with the same secondary antiserum and detection with the ECL system. Quantification of hRAD51 overexpression was done by comparison of serial dilutions of extracts from phRAD51neo-or phRAD51Rneo-transfected cells with control extracts containing normal amounts of hRAD51.
FACS analysis
Flow cytometry of propidium iodide-stained cell nuclei was carried out as previously described, 39 using a FACScan and the CellQuest software (Becton Dickinson). Quantification of populations with different DNA content in histogram plots was done with program ModFit LT (Verity Software House).
Statistical analyses
The STATA software package (STATA Corporation) was used to carry out two-sample t tests and ANOVAs on log-transformed data.
